The Patent Finder

Windtree Therapeutics, Inc.

Also on record
Records under this name other than the patents Windtree Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 13 patents it holds.

Back to Windtree Therapeutics, Inc.

PatentTitleStatus Expires Confidence
US 11,197,869Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure (AHF)
In force
 · Medium confidence
In forceMedium confidence
US 11,583,540Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure (AHF)
In force
 · Low confidence
In forceLow confidence
US 12,343,350Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure (AHF)
In force
 · Medium confidence
In forceMedium confidence
US 12,503,484Androstane Derivatives with Activity as Pure or Predominantly Pure Stimulators of SERCA2a for the Treatment of Heart Failure.
In force
 · High confidence
In forceHigh confidence
US 7,541,331Surfactant Treatment Regimen
Term ended
Term ended Jan 6, 2026 · High confidence
Term endedTerm ended Jan 6, 2026High confidence
US 7,582,312Methods to Produce Lung Surfactant Formulations via Lyophilization and Formulations and Uses Thereof
Lapsed on the fee record
Ended Sep 1, 2017 · High confidence
Lapsed on the fee recordEnded Sep 1, 2017High confidence
US 8,337,815Pulmonary Surfactant Formulations
Lapsed on the fee record
Ended Dec 25, 2016 · High confidence
Lapsed on the fee recordEnded Dec 25, 2016High confidence
17/598,719Inhibitors of Atypical Protein Kinase C and Their Use in Treating Hedgehog Pathway-Dependent Cancers
Abandoned
Abandoned Apr 28, 2026
AbandonedAbandoned Apr 28, 2026
18/858,086Istaroxime-Containing Intravenous Formulation for the Treatment of Pre-Cardiogenic Shock and Cardiogenic Shock
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
19/139,166Solid Forms of {5-Cyclopropyl-2-[2-(3,6-difluoro¬pyridin-2-ylamino)-pyridin-4-yl]-pyrido[3,4-d]pyrimidin-4-yl }-( (S)-3,3-Dimethyl-PIPERIDIN-4-YL)-AMINE
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
10 of 11 records shown.
Pro members see all 11.
Pro members: see all 11 records
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited